Gene therapy has always been controversial, mostly because it got off to a promising start and then floundered for almost a decade. But now it is the “comeback kid” of biotech, and is involved in almost 600 clinical trials in 20 countries.
There has been only one gene-therapy related death and researchers have been able to trace what went wrong thereby being able to avoid such an outcome in the future.
Source: Michael Fumento (Hudson Institute), A New Start for Gene Therapy, Washington Times, October 31, 2002.
For text http://www.washtimes.com/commentary/20021031-11641000.htm
For more on Medical Research http://www.ncpa.org/iss/hea
FMF Policy Bulletin \7 November 2002
